$XCUR:NASDAQ · EXICURE, INC.
Conviction from: NASDAQ
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd.
More about this company
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-01-21 | SCHEDULE 13D/A | Exicure HiTron Inc. | 25.1% | Med | filing |
| 2026-01-20 | SCHEDULE 13D/A | Exicure HiTron Inc. | 29.2% | Med | filing |
| 2026-01-09 | SCHEDULE 13D/A | Exicure HiTron Inc. | 40.7% | Med | filing |